Roche doubles down in Fight against Antibiotic Resistance

In 2014, Discuva partnered up with Roche to develop new antibiotics against multidrug-resistant bacteria. The two companies have announced an extension of their collaboration until February 2018.

The Cambridge-based company Discuva wants to address the critical need for new antibiotic drugs to treat infections from multidrug-resistant bacteria. Posing a major public health threat, antibiotic resistances cause at least 25,000 deaths per year in Europe alone due to lack of alternative medicines.

In 2014, Roche and Discuva entered a worldwide collaboration and license agreement for the discovery and development of new antibiotics effective against infections, which are otherwise impervious to treatment. The partnership is based on Discuva’s SATItechnology, a next-generation sequencing and bioinformatics platform applied to unique bacterial transposon libraries. This…

Read the full article from the Source…

Back to Top